行情

ALNY

ALNY

阿里拉姆制药
NASDAQ

实时行情|Nasdaq Last Sale

152.30
+6.54
+4.49%
盘后: 152.30 0 0.00% 17:36 08/03 EDT
开盘
146.79
昨收
145.76
最高
153.01
最低
145.58
成交量
41.28万
成交额
--
52周最高
167.33
52周最低
69.11
市值
174.87亿
市盈率(TTM)
-18.9735
分时
5日
1月
3月
1年
5年

分析师评级

21位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ALNY价格均价为163.45,最高价位202.00,最低价为89.00。

EPS

ALNY 新闻

更多
Alnylam Submits a Clinical Trial Authorization Application for ALN-HSD to UK Regulatory Bodies
Company Expects to Initiate a Phase 1 Study in Late 2020
Benzinga · 11小时前
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4天前
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 6天前
Pfizer Surges On Coronavirus Vaccine Supply Deals But Is PFE Stock A Buy?
Investor's Business Daily · 07/27 15:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
A Top Contender in the Race for a NASH Drug Drops Out
French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.
Barrons.com · 07/23 15:02
Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2020 on Thursday, August 6, 2020, before the U.S. financial markets open.
Business Wire · 07/23 12:00
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:59

所属板块

生物技术和医学研究
+3.60%
制药与医学研究
+2.08%

热门股票

代码
价格
涨跌幅

ALNY 简况

Alnylam Pharmaceuticals, Inc.是一家生物制药公司。该公司从事核糖核酸(RNA)干扰(RNAi)治疗剂的发现、开发和商业化。该公司专注于使用其N-乙酰半乳糖胺(GalNAc)共轭平台来递送小干扰RNA(siRNA)。其研究性RNAi治疗药物的研发重点集中在三个战略治疗领域(STArs):遗传药物,具有多种治疗罕见病的候选药物;心血管疾病,其候选产品针对经过遗传验证的、肝表达的疾病靶标以满足未满足的心血管疾病和代谢疾病的需求;以及肝感染性疾病,其候选产品旨在解决从肝炎开始的肝感染性疾病的全球健康挑战乙型和丁型肝炎病毒感染。
展开

微牛提供Alnylam Pharmaceuticals, Inc.(NASDAQ-ALNY)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ALNY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ALNY股票基本功能。